A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain

Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response

(2021) Qiu-dong Su et al.   VACCINE

Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

(2021) Cyrielle Fougeroux et al.   Nature Communications

SARS-CoV-2 structural features may explain limited neutralizing-antibody responses

(2021) Martin F. Bachmann et al.   npj Vaccines

Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities

(2021) Maria G. Noval et al.   Scientific Reports

Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019

(2021) Jingyuan Liu et al.   Frontiers in Pharmacology

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

(2021) Robert H Shaw et al.   LANCET

Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles

(2021) Lisha Zha et al.   Vaccines

AP205 VLPs Based on Dimerized Capsid Proteins Accommodate RBM Domain of SARS-CoV-2 and Serve as an Attractive Vaccine Candidate

(2021) Xuelan Liu et al.   Vaccines

A scalable and highly immunogenic virus‐like particle‐based vaccine against SARS‐CoV‐2

(2021) Mona O. Mohsen et al.   ALLERGY

Spike protein fusion loop controls SARS-CoV-2 fusogenicity and infectivity

(2021) Debnath Pal   JOURNAL OF STRUCTURAL BIOLOGY

Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS

(2020) Yushun Wan et al.   JOURNAL OF VIROLOGY

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

Immunization of Cats against Fel d 1 Results in Reduced Allergic Symptoms of Owners

(2020) Franziska Thoms et al.   Viruses-Basel

Cell entry mechanisms of SARS-CoV-2

(2020) Jian Shang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

(2020) Chek Meng Poh et al.   Nature Communications

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

(2020) Jingyun Yang et al.   NATURE

Potently neutralizing and protective human antibodies against SARS-CoV-2

(2020) Seth J. Zost et al.   NATURE

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

(2020) Thomas F. Rogers et al.   SCIENCE

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

(2020) Shengli Xia et al.   LANCET INFECTIOUS DISEASES

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

(2020) Alina Baum et al.   SCIENCE

A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate

(2020) Lorena Sanchez-Felipe et al.   NATURE

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

(2020) David M. Weinreich et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

(2020) Peter Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhanced SARS-CoV-2 neutralization by dimeric IgA

(2020) Zijun Wang et al.   Science Translational Medicine

Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19

(2020) Carlo Cervia et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

(2020) Yanjun Zhang et al.   LANCET INFECTIOUS DISEASES

Antibody responses to viral infections: a structural perspective across three different enveloped viruses

(2019) Charles D. Murin et al.   Nature Microbiology

Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects

(2019) Franziska Thoms et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

RNA and Toll-Like Receptor 7 License the Generation of Superior Secondary Plasma Cells at Multiple Levels in a B Cell Intrinsic Fashion

(2019) Caroline C. Krueger et al.   Frontiers in Immunology

Type of RNA Packed in VLPs Impacts IgG Class Switching—Implications for an Influenza Vaccine Design

(2019) Ariane C. Gomes et al.   Vaccines

Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergens

(2019) Federico Storni et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

HPV vaccines – A review of the first decade

(2017) Diane M. Harper et al.   GYNECOLOGIC ONCOLOGY

Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy

(2017) Andris Zeltins et al.   npj Vaccines